1. Home
  2. CYD vs DMRA Comparison

CYD vs DMRA Comparison

Compare CYD & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo China Yuchai International Limited

CYD

China Yuchai International Limited

HOLD

Current Price

$54.68

Market Cap

1.6B

Sector

Industrials

ML Signal

HOLD

DMRA

Damora Therapeutics Inc. Common Stock

N/A

Current Price

$25.76

Market Cap

1.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CYD
DMRA
Founded
1951
2011
Country
Singapore
United States
Employees
N/A
7
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.5B
IPO Year
1998
2020

Fundamental Metrics

Financial Performance
Metric
CYD
DMRA
Price
$54.68
$25.76
Analyst Decision
Strong Buy
Buy
Analyst Count
1
2
Target Price
$60.00
$43.00
AVG Volume (30 Days)
193.2K
318.6K
Earning Date
02-24-2026
05-11-2026
Dividend Yield
1.32%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$15.11
N/A
Revenue Next Year
$8.67
N/A
P/E Ratio
$32.71
N/A
Revenue Growth
N/A
N/A
52 Week Low
$16.77
$16.50
52 Week High
$61.48
$28.76

Technical Indicators

Market Signals
Indicator
CYD
DMRA
Relative Strength Index (RSI) 63.77 52.46
Support Level $35.24 $24.80
Resistance Level $56.55 $26.73
Average True Range (ATR) 3.00 1.51
MACD 0.59 0.12
Stochastic Oscillator 58.48 74.94

Price Performance

Historical Comparison
CYD
DMRA

About CYD China Yuchai International Limited

China Yuchai International Ltd is a Bermuda holding company that is a subsidiary of Singapore-based Hong Leong Asia. China Yuchai International operates through its majority-owned subsidiary Guangxi Yuchai Machinery Company, a China-based company that manufactures, assembles, and distributes diesel engines for various vehicles including trucks, buses, and cars, as well as construction and agricultural, marine, and power-generation equipment. It generates the majority of its sales from the Chinese market.

About DMRA Damora Therapeutics Inc. Common Stock

Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.

Share on Social Networks: